Subsequently, PARP inhibitors have shown efficacy in the second line, and olaparib, rucaparib and niraparib have now been approved as maintenance therapy for HR deficient ovarian cancer patients following platinum-based chemotherapy45–47. The gene discussed is PARP1; the disease is ovarian carcinoma.